The Blood and Marrow Transplant Clinical Trials Network (BMT CTN) conducts large, multi-institutional clinical trials with the goal of improving the outcomes of hematopoietic cell transplantation (HCT) for patients with life-threatening disorders. Well-designed HCT trials benefit from standardized criteria for defining diagnoses, treatment plans, and graft source selection. In this perspective, we summarize evidence supporting criteria for the selection of related and unrelated adult volunteer progenitor cell donors or umbilical cord blood units. These standardized criteria for graft source selection have been adopted by the BMT CTN to enhance the interpretation of clinical findings within and among future clinical protocols.

作者：C Alan, Howard；Marcelo A, Fernandez-Vina；Frederick R, Appelbaum；Dennis L, Confer；Steven M, Devine；Mary M, Horowitz；Adam, Mendizabal；Ginna G, Laport；Marcelo C, Pasquini；Stephen R, Spellman

来源：Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2015 年 21卷 1期